Noticias Científicas
· The tool is based on Chemical Checker technology, developed by the Structural Bioinformatics and Network Biology Laboratory at IRB Barcelona.
· The aim is to use artificial intelligence to generate a drug database that includes all the published scientific results related to the treatment of COVID-19.
· This open access database will provide researchers from around the world with an expanded portfolio of molecules with the potential to fight COVID-19.
The ICREA researcher at IRB Barcelona obtains €2.5 M to identify residual cells that cause relapse after treatment.
This is the fifth ERC grant awarded to Eduard Batlle, and the 20th at IRB Barcelona.
The study, published in the journal Developmental Cell and performed in Drosophila, unravels how developmental genes regulate organ size and proportions.
Researchers at IRB Barcelona demonstrate that the size and patterning of a given organ are regulated by different mechanisms.
Given the high genetic and mechanistic conservation between flies and humans, these discoveries pave the way for new research lines into congenital malformations and other diseases
- Pan-Cancer Project discovers causes of previously unexplained cancers, pinpoints cancer-causing events and zeroes in on mechanisms of development
- IRB Barcelona researchers, as part of an international team, contribute to the most comprehensive study of whole cancer genomes to date, significantly improving our fundamental understanding of cancer and signposting new directions for its diagnosis and treatment.
The study infers the genetic changes that coincided with the appearance of different groups of animals and their main traits.
Researchers at IRB Barcelona and BSC-CNS have confirmed that the dynamics of genomic evolution, in addition to the presence or absence of the genes themselves, determines diversity in the animal kingdom.
Published in Nature Ecology and Evolution, the study has been based for the first time on the genomic data of all the large groups of animals.
Ángel Nebreda’s team has published a study in the journal PNAS reporting the involvement of the protein p38 in the progression of lung cancer.
The work shows that patients with low levels of this protein have a better prognosis.
One of the biggest challenges faced by biomedicine is the development of more selective and efficient cancer treatments.
This species shows several genetic duplications, which may explain its high plasticity and capacity to adapt to diverse farming conditions.
CSIC has headed this research, which has brought about a considerable advance in the development of genomic and biotechnological tools to achieve more sustainable fish farming.
The findings of the study will be applied in genetic selection and environmental programming in order to improve fish quality and interaction with the microorganisms present in the host environment.
Published in the journal Nature Cancer, the study analyses how genetic alterations in tumour cells prevent the correct degradation of the proteins involved in tumour development and growth, thereby leading to abnormal cell behaviour.
A machine-learning model has allowed the scientists to obtain the most extensive annotation of the ubiquitin-mediated protein degradation system.
The analysis proposes a potential new clinical approach for cancer through the inhibition of oncoproteins with impaired degradation systems.
Scientists at IRB Barcelona determine the genetic alterations in the cells of cancer patients caused by the main cancer therapies.
This is an important step towards understanding the long-term side effects and optimizing treatments against cancer.
The results have been published in the journal Nature Genetics.
Both transcription factors regulate the expression of genes involved in embryo development, among other functions, although they exert very different roles.
The study also refutes the theory accepted to date that SMAD2 does not bind to DNA.
Published in Genes & Development, the research is the result of collaboration between Maria J. Macias’ lab at IRB Barcelona and Joan Massagué’s group at the Sloan Kettering Institute (New York, US).
